
Brand Name | Status | Last Update |
|---|---|---|
| adriamycin | ANDA | 2024-04-11 |
| doxil | New Drug Application | 2026-03-10 |
| doxorubicin hydrochloride | ANDA | 2026-11-03 |
| doxorubicin hydrochloride liposome | ANDA | 2026-02-24 |
| doxorubicin hydrochloride, liposomal | unapproved drug for use in drug shortage | 2023-12-19 |
| oxderys | New Drug Application | 2026-11-12 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 8 | 4 | — | — | 12 |
| Hodgkin disease | D006689 | — | C81 | 1 | 4 | 1 | — | — | 5 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 2 | — | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | 1 | 2 | — | — | — | 2 |
| T-cell lymphoma | D016399 | — | — | 1 | 1 | — | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Philadelphia chromosome | D010677 | — | — | 1 | — | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | 1 | — | — | — | — | 1 |
| Drug common name | Doxorubicin |
| INN | doxorubicin |
| Description | Doxorubicin is a deoxy hexoside, an anthracycline, an anthracycline antibiotic, an aminoglycoside, a member of tetracenequinones, a member of p-quinones, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It has a role as an Escherichia coli metabolite. It is a conjugate base of a doxorubicin(1+). It derives from a hydride of a tetracene. |
| Classification | Small molecule |
| Drug class | antineoplastic antibiotics (daunorubicin type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 |
| PDB | — |
| CAS-ID | 23214-92-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL53463 |
| ChEBI ID | 28748 |
| PubChem CID | 31703 |
| DrugBank | DB00997 |
| UNII ID | 80168379AG (ChemIDplus, GSRS) |






